ttr-1 Antibody

Overview of TTR-1 Antibody

The TTR-1 Antibody (clone CPTC-TTR-1) is a mouse-derived IgG2a monoclonal antibody generated against recombinant full-length human TTR protein . It binds to both native and misfolded forms of TTR, making it valuable for studying TTR-related amyloidosis, a condition where misfolded TTR aggregates form pathogenic fibrils in tissues like the heart and nerves .

Key Features:

Epitope Specificity:

The antibody binds to a linear epitope within the C-terminal region (amino acids 71–98) of TTR, as confirmed by peptide immunization and protein array analyses . Its specificity is validated by high Z-scores (>30) and S-scores (>29) in HuProt™ protein arrays, indicating minimal cross-reactivity .

Diagnostic and Experimental Uses

• Western Blot: Detects TTR at ~15 kDa in human liver lysates .

• Protein Arrays: Identifies TTR among 19,000 human proteins with high specificity .

• Immunohistochemistry: Stains TTR deposits in cardiac tissues from amyloidosis patients .

Therapeutic Potential

While CPTC-TTR-1 itself is primarily a research tool, structurally similar antibodies (e.g., NI301A, T24) have demonstrated therapeutic efficacy in preclinical models by:

1. Promoting phagocytic clearance of TTR aggregates via macrophages .

2. Reducing cardiac amyloid burden in vivo .

3. Protecting cardiomyocytes from TTR-induced toxicity .

In Vitro and Ex Vivo Studies

• Amyloid Binding: CPTC-TTR-1 binds amyloid-positive TTR deposits in human heart tissues but not normal tissues .

• Cross-Reactivity: Does not recognize other amyloid types (e.g., Aβ or AL) .

Preclinical Data from Related Antibodies

Limitations and Future Directions

• Species Restriction: Primarily validated for human and rat samples .

• Therapeutic Gap: Unlike NI301A or T24, CPTC-TTR-1 lacks in vivo therapeutic data, highlighting a need for translational studies .